Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for immune resetCandid’s lead asset, cizutamig, a bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results